Back | Next |
home / stock / avxl / avxl message board
Subject | By | Source | When |
---|---|---|---|
You can see why the simufilam p2 results | Hoskuld | investorshub | 07/20/2024 7:12:06 PM |
Thanks. Much appreciated. | abew4me | investorshub | 07/20/2024 7:06:22 PM |
https://www.fda.gov/media/168664/download | Hoskuld | investorshub | 07/20/2024 6:40:45 PM |
Do you have a link for this FDA | abew4me | investorshub | 07/20/2024 6:29:50 PM |
Take a look at this recent peer reviewed | Pazzo1212 | investorshub | 07/20/2024 4:57:24 PM |
Does Anavex know if and when the peer | Jonjones325 | investorshub | 07/20/2024 4:16:53 PM |
Because it has not yet been approved and | Steady_T | investorshub | 07/20/2024 4:07:06 PM |
If drug works then why stock is stuck | kund | investorshub | 07/20/2024 4:00:04 PM |
Data and analysis have already been released. | Hoskuld | investorshub | 07/20/2024 3:26:35 PM |
Yep, he is busy backing up imaginary data | kund | investorshub | 07/20/2024 3:01:16 PM |
We have the Safety. Missing needs to release | Reyeton | investorshub | 07/20/2024 2:36:02 PM |
All honest longs here know the answer is | cfoofme | investorshub | 07/20/2024 2:11:08 PM |
Although knowing missling, he probably has a back | taketobank | investorshub | 07/20/2024 1:08:21 PM |
I hope none of our data was on | taketobank | investorshub | 07/20/2024 1:07:24 PM |
Cloudstrike screwup sb Crowdstrikeoops ! | plexrec | investorshub | 07/20/2024 12:35:02 PM |
Steady T | sab63090 | investorshub | 07/20/2024 11:20:46 AM |
The Cloudstrike screwup had a major effect on | Steady_T | investorshub | 07/20/2024 5:35:16 AM |
O.T. already approved huh. There HAS to be something | Rubyred77 | investorshub | 07/20/2024 4:38:07 AM |
It is an Open Label Extension to the | Steady_T | investorshub | 07/20/2024 4:36:54 AM |
No, the real reason you havent been sued | ignatiusrielly35 | investorshub | 07/20/2024 4:33:27 AM |
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
Oral, once daily blarcamesine significantly slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events Clinical benefit of blarcamesine consistently observed for both 30 mg and 50 mg treatment groups ...
2024-07-18 02:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsyc...